Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors

Critical Reviews in Oncology/Hematology

Volumn 38, Issue 3, 2001, Pages 177-192

  Galanis, Evanthia ^a   Vile, Richard ^a   Russell, Stephen J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cancer gene therapy; Replicating vectors; Targeting

Indexed keywords

VIRUS GLYCOPROTEIN;

ADENOVIRUS; CANCER THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; DNA MODIFICATION; DNA VECTOR; EPSTEIN BARR VIRUS; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSCRIPTION; HERPES SIMPLEX VIRUS; HUMAN; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PROSTATE CANCER; REOVIRUS; RETROVIRUS; REVIEW; TOXICITY; TUMOR CELL; VIRUS; VIRUS MUTANT; VIRUS REPLICATION;

DNA REPLICATION; DRUG DELIVERY SYSTEMS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; VIRUSES;

EID: 0035030198     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00103-2     Document Type: Review

References (124)

1. Seemayer T.A., Cavenee W.K. Molecular mechanisms of oncogenesis. Lab. Invest. 60:1989;585-599.
2. Gutierrez A.A., Lemoine N.R., Sikora K. Gene therapy for cancer. Lancet. 339:1992;715-721.
3. Sokora K. Gene therapy for cancer. Trends Biotechnol. 11:1993;197-201.
4. Anderson W.F. Human gene therapy. Science. 256:1992;808-813.
5. Roth J.A., Cristiano R.J. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst. 89:1997;21-39.
6. Gunzburg W.H., Salmons B. Development of retroviral vectors as safe, targeted gene delivery systems. J. Mol. Med. 74:1996;171-182.
7. Weiss R. Cellular receptors and viral glycoproteins involved in retrovirus entry. Levy J.A. The retroviridae. 1993;1-108 Plenum Press, New York.
8. Weiss R., Tailor C. Retrovirus receptors. Cell. 82:1995;531-533.
9. Burns J., et al. Vesicular stomatitis virus G-glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA. 90:1993;8033-8037.
10. Reiser J., et al. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc. Natl. Acad. Sci. USA. 93:1996;15266-15271.
11. +/CD38 cells in extended long term culture using a lentiviral vector. Proc Am Soc Gene Ther 1998;104a.
12. Kasahara N., Dozy A.M., Kan Y.W. Tissue specific targeting of retroviral vectors through ligand-receptor interactions. Science. 266:1994;1373-1376.
13. Han X., Kasahara N., Kan Y.W. Ligand-directed retroviral targeting of human breast cancer cells. Proc. Natl. Acad. Sci. USA. 92:1995;9747-9751.
14. Matano T., et al. Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1. J. Gen. Virol. 76:1995;3165-3169.
15. Cosset F.L., et al. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J. Virol. 69:1995;6314-6322.
16. Marin M., Noel D., Piechaczyk M. Towards efficient cell targeting by recombinant retroviruses. Mol. Med. Today. 3:1997;396-403.
17. Russell S., Hawkins R., Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res. 21:1993;1081-1085.
18. Somia N., Zoppe M., Verma I. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc. Natl. Acad. Sci. USA. 92:1995;7570-7574.
19. Marin M., et al. Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment envelope fusion proteins. J. Virol. 70:1996;2957-2962.
20. Ager S., et al. Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Hum. Gene Ther. 7:1996;2157-2164.
21. Schnierle B., et al. Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles. Gene Ther. 3:1996;334-342.
22. Valsesia W.S., et al. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J. Virol. 68:1994;4609-4619.
23. Nilson B., et al. Targeting of retroviral vectors through protease-substrate interactions. Gene Ther. 3:1996;280-286.
24. Peng K.W., Morling F.J., Cossett F.L., Murphy G., Russell S.J. A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum. Gene Ther. 8:1997;729-738.
25. Peng K.-W., Vile R.G., Cosset F.-L., Russell S.J. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther. 6:1999;1552-1557.
26. Jiang A., Chu T.H., Nocken F., Cichutek K., Dornburg R. Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies. J. Virol. 72:1998;10148-10156.
27. Roux P, Jeanteur P, Piechaczyk M. Cell targeting by recombinant retrovirus using bi-specific antibody complexes. In: NATO Advanced Study Institute Series: subseries "Cell biology," "Vectors as tools for the study of normal and abnormal growth and differentiation," Berlin: Springer, 1989, p. 153-64.
28. Roux P., Jeanteur P., Piechaczyk M. A versatile and potentially general approach to the targeting of specific cells by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses. Proc. Natl. Acad. Sci. USA. 86:1989;9079-9083.
29. Etienne-Julan M., et al. The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. J. Gen. Virol. 73:1992;3251-3255.
30. Snitkovsky S., Young J.A. Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein. Proc. Natl. Acad. Sci. USA. 95:1998;7063-7068.
31. Svoboda J. Molecular biology of cell nonpermissiveness to retroviruses. Has the time come? Gene. 206:1998;153-163.
32. Bucholz C.J., Peng K.-W., Morling F.J., Zhang J., Cosset F.L., Russell S.J. In vivo selection of protease cleavage sites from retrovirus display libraries. Nature Biotechnol. 16:1998;951-954.
33. Philipson L., Lonberg-Holm K., Pettersson U. Virus-receptor interaction in an adenovirus system. J. Virol. 2:1968;1064-1075.
34. Wickham T.J., Mathias P., Cheresh D.A., Nemerow G.R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 73:1993;309-319.
35. Louis N., Fender P., Barge A., Kitts P., Chroboczek J. Cell-binding domain of adenovirus serotype 2 fibr. J. Virol. 68:1994;4104-4106.
36. Henry L.J., Xia D., Wilke M.E., Deisenhofer J., Gerard R.D. Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli. J. Virol. 68:1994;5239-5246.
37. Varga M.J., Weibull C., Everitt E. Infectious entry pathway of adenovirus type 2. J. Virol. 65:1991;6061-6070.
38. Greber U.F., Willetts M., Webster P., Helenius A. Stepwise dismantling of adenovirus 2 during entry into cells. Cell. 75:1993;477-486.
39. Weitman S.D., Lark R.H., Coney L.R., et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52:1992;3396-3401.
40. Douglas J.T., Rogers B.E., Rosenfeld M.E., Michael S.I., Feng M., Curiel D.T. Targeted gene delivery by tropism-modified adenoviral vectors. Nature Biotechnol. 14:1996;1574-1578.
41. Baird A., Klagsbrun M. The fibroblast growth factor family. Cancer Cells. 3:1991;239-243.
42. Douglas J.T., Curiel D.T. Targeted adenoviral vectors for cancer gene therapy. Intl. J. Oncol. 11:1997;341-348.
43. Li J.J., Huang Y.Q., Moscatelli D., Nicolaides A., Zhang W.C., Friedman-Kien A.E. Expression of fibroblast growth factors and their receptors in acquired immunodeficiency syndrome-associated Kaposi sarcoma tissue and derived cells. Cancer. 72:1993;2253-2259.
44. Rancourt C., Rogers B.E., Sosnowski B.A., et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin. Cancer Res. 4:1998;2455-2461.
45. Miller C.R., Buchsbaum D.J., Reynolds P.N., et al. Differential susceptibility of primary and established human gliomas cells to adenovirus infection: targeting via receptor-independent gene transfer. Cancer Res. 58:1998;5738-5748.
46. Watkins S.J., Mesyanzhinov V.V., Kurochkina L.P., Hawkins R.E. The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther. 4:1997;1004-1012.
47. Wickham T.J., Roelvink P.W., Brought D.E., Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nature Biotechnol. 14:1996;1570-1573.
48. Hong J.S., Engler J.A. Domains required for assembly of adenovirus type 2 fiber trimers. J. Virol. 70:1996;7071-7078.
49. Dmitriev I., Krasnykh V., Miler C.R., Wang M., Kashentseva E., et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 72:1998;9706-9713.
50. Wickham T.J., Segal D.M., Roelvink P.W., et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J. Virol. 70:1996;6831-6838.
51. Bilbao G., Gomez-Navarro J., Curier D.T. Targeted adenoviral vectors for cancer gene therapy. Adv. Exp. Med. Biol. 451:1998;365-374.
52. Barry M.A., Dower W.J., Johnston S.A. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phase libraries. Nature Med. 2:1996;299-305.
53. Pasqualini R., Ruoslahti E. Organ targeting in vivo using phase display peptide libraries. Nature. 380:1996;364-366.
54. Pieroni L, Fipaldini C, Monciotti A, Cimini D, Sgura A, et al. Targeted integration of adeno-associated virus derived plasmids in transfected human cells Virology 1998;249(9):249-59.
55. Yang Q., Mamounas M., Yu G., et al. Development of novel cell surface CD34-targeted recombinant adeno-associated virus vectors for gene therapy. Hum. Gene Ther. 9:1998;1929-1937.
56. Bartlett J.S., Kleinschmidt J., Boucher R.C., Samulski R.J. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab′gamma) 2 antibody. Nature Biotechnol. 17:1999;181-186.
57. Ohno K., Sawai K., Iijima Y., Levin B., Meruelo D. Cell specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nature Biotechnol. 15:1997;763-767.
58. Iijima Y., Ohno K., Ikeda H., Sawai K., Levi B., Meruelo D. Cell specific targeting of a thymidine kinase/ganciclovir gene therapy system using a recombinant Sindbis virus vector. Intl. J. Cancer. 80:1999;110-118.
59. Laquerre S., Anderson D.B., Stolz D.B., Glorioso J.C. Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J. Virol. 72:1998;9683-9697.
60. Hanahan D. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 315:1985;115-122.
61. Dale T.C., Krnacik M.J., Schmidhauser C., Yang C.L.-Q., Bissel M.J., Rosen J.M. High-level expression of the rat whey acidic protein gene is mediated by elements in the promoter and 3′ untranslated region. Mol. Cell Biol. 12:1992;905-914.
62. Vile R.G., Hart I.R. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53:1993;962-967.
63. Brenner M., Kisselberth W.C., Su Y., et al. GFAP promoter directs astrocyte specific expression in transgenic mice. J. Neurosci. 14:1994;1030-1037.
64. Huber B.E., Richard C.A., Krenitsky T.A. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA. 88:1991;8039-8043.
65. Friedman J.M., Babiss L.E., Clayton D.F., Darnell J.E. Cellular promoters incorporated into the adenovirus genome: cell specificity of albumin and immunoglobulin expression. Mol. Cell Biol. 6:1986;3791-3797.
66. Osaki T., Tanio Y., Tachibana I., et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 54:1994;5258-5261.
67. Krimpenfort P., de Jong R., Uematsu Y., et al. Transcription of T-cell receptor β-chain genes is controlled by a downstream regulatory element. EMBO J. 7:1988;745-750.
68. Murtha P., Tindall D.J., Young C.Y.F. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry. 32:1993;6459-6464.
69. Garver R.I., Goldsmith K.T., Rodu B., Hu P.C., Sorscher E.J., Curiel D.T. Strategy for achieving selective killing of carcinomas. Gene Ther. 1:1994;46-50.
70. Hollywood D.P., Hurst H.C. A novel transcription of factor, OB2-1, is required for overexpression of the oncogene c-erb-w in mammary tumor lines. Embo J. 12:1993;2369-2375.
71. Harris J.D., Gutierrez A.A., Hurst H.C., Sikora K., Lemoine N.R. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther. 2:1995;681.
72. Kumagai T., Tanio Y., Osaki T., Horai T., Kishimoto T. Gene therapy for small cell lung cancer cells overexpressing myc family oncogenes by tumor-specific expression of the herpes simplex virus thymidine kinase gene. Gene Ther. 2:1995;681.
73. Nelson K.L., Becker N.A., Pahwa G.S., Hollingsworth M.A., Maher L.J. Potential for H-DNA in the human MUC1 mucin gene promoter. J. Biol. Chem. 271:1996;18061-18067.
74. Ko S.C., Cheon J., Kao C.H., et al. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res. 56:1996;4614-4619.
75. Rixe O., Calvez V., Mouawad R., et al. Transactivation of the metallothionein promoter in cisplatin (CP) resistant cell lines: potential application for a specific gene therapy. Proc. Am. Assoc. Cancer Res. 36:1995;200.
76. Weichselbaum R.R., Hallahan D.E., Beckette M.A., et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res. 54:1994;4266-4269.
77. Hallahan D.E., Mauceri H.J., Seung L.P., et al. Spatial and temporal control of gene therapy using ionizing radiation. Nature Med. 1:1995;786-791.
78. Mauceri H.J., Hanna N.N., Wayne J.D., Hallahan D.E., Hellman S., Weichselbaum R.R. Tumour necrosis factors alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages the tumour vasculature. Cancer Res. 56:1996;4311-4314.
79. Dachs G.U., Patterson A.V., Firth J.D., et al. Targeting gene expression to hypoxic tumour cells. Nature Med. 3:1997;515-520.
80. Kijima T., Osaki T., Nishino K., et al. Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. Cancer Res. 59:1999;4906-4911.
81. Russell S.J. Replicating vectors for gene therapy of cancer: risks, limitations and prospects. Eur. J. Cancer. 30A:1994;1165-1171.
82. Parrish C.R. Emergency, natural history, and variation of canine, mink and feline parvoviruses. Adv. Virus Res. 38:1990;403-451.
83. Asada T. Treatment of human cancer with mumps virus. Cancer. 34:1974;1907-1928.
84. Smith R. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 9:1956;1211-1218.
85. Horwitz M.S. Adenoviridae and their replication. Fields B.N., et al. Virology. 1990;1679-1721 Raven Press, New York.
86. Bischoff J.R., Kirn D.H., Williams A., et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:1996;373-376.
87. Rothman T., Hengstermann A., Whitaker N.J., Scheffner M., zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72:1998;9470-9478.
88. Goodrum F.D., Ornelles D.A. p53 status does not determine outcome of E1B 55-Kilodalton mutant adenovirus lytic infection. J. Virol. 72:1998;9479-9490.
89. Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D.D., Kirn D.H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. 3:1997;639-645.
90. Heise C., Williams A., Propst M., Sampson-Johannes A., et al. Preclinical studies with ONYX-015 (a replication competent E1B-deleted adenovirus) in combination with chemotherapy. Cancer Gene Ther. 4:1997;S13.
91. Nemunaitis J., Khuri F., Ganly I., et al. Phase II trials of intratumoral ONYX-015, an E1B 55-kDa gene-deleted adenovirus, alone and in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Cancer Gene Ther. 5:1998;S26.
92. Mulvihill S.J., Warren R.S., Fell S., et al. A phase I trial of intratumoral injection with an E1B-attenuated adenovirus, ONYX-015, into unresectable carcinomas of the exocrine pancreas. Proc. Am. Soc. Clin. Oncol. 17:1998;211a.
93. Bergsland E., Mani S., Kirn D., et al. Intratumoral injection of ONYX-015 for gastrointestinal tumors metastatic to the liver: a phase I trial. Proc. Am. Soc. Clin. Oncol. 17:1998;211a.
94. Vasey P.A., Seiden M., O'Neill V., Campo S., Jonston S., et al. Phase I trial of intraperitoneal onyx-015 adenovirus in patients with recurrent ovarian cancer. Proc. ASCO. 19:2000;382a.
95. Khuri F.R., Nemunaitis J., Khuri F., Ganly I., Arseneau J., et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Med. 6:(8):2000;879-885.
96. Rodriguez R., Schuur E.R., Lim H.Y., Henderson G.A., Simons J.W., Henderson D.R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57:1997;2559-2563.
97. Whitley R.J. Herpes simplex viruses. Fields B.N., Knipe D.M., Howley P.M. Fields virology. 1996;2297-2342 Lippincott-Raven, Philadelphia.
98. Lachmann R.H., Efstathiou S. The use of herpes simplex virus-based vectors for gene delivery to the nervous system. Mol. Med. Today. 3:1997;404-411.
99. Roizmann B., Sears A.E. Herpes simplex viruses and their replication. Fields B.N., Knipe D.M., Howley P.M. Fields virology. 1996;2231-2295 Lippincott-Raven, Philadelphia.
100. Martuza R.L., Malick A., Markert J., Ruffner K.L., Coen D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 252:1991;854-856.
101. Coen D.M., et al. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc. Natl. Acad. Sci. USA. 86:1989;4736-4740.
102. Mineta T., Rabkin S.D., Martuza R.L. Tratment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 56:1994;3963-3966.
103. Boviatsis E.J., et al. Antitumor activity and reporter gene transfer into rat brain endoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther. 1:1994;323-331.
104. Chou J., Kern E.R., Whitley R.J., Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture. Science. 250:1990;1262-1266.
105. Mineta T., Rabkin S.D., Yazaki T., Hunter W.D., Martuza R.L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. 1:1995;938-943.
106. Yazaki T., Manz H.J., Rabkin S.D., Martuza R.L. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 55:1995;4752-4756.
107. Markert J.M., Medlock M., Rabkin S.D., Gillespie G.Y., et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7:2000;867-874.
108. Andreansky S., He B., van Cott J., et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 5:1998;121-130.
109. Chase M., Chung R.Y., Chiocca E.A. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nature Biotechnol. 16:1998;444-448.
110. Miyatake S.I., Iyer A., Martuza R.L., Rabkin S.D. Trascriptional targeting of herpes simplex virus for cell-specific replication. J. Virol. 71:1997;5124-5132.
111. Westphal E.M., Mauser A., Swenson J., Davis M.G., Talarico C.L., Kenney S.C. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo. Cancer Res. 59:1999;1485-1491.
112. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689.
113. Strong J.E., Coffey M.C.V., Tang D., Sabinin P.W.K. The molecular basis of viral oncolysis: usurpation of the ras signaling pathway by reovirus. EMBO J. 17:1998;3351.
114. Tyler K.L., Fields B.N. Fields B.N., Knipe D.M., Howley P.M. Fields virology. 1996;1597-1623 Lippincott-Raven, Philadelphia.
115. Coffey M.C., Strong J.E., Forsyth P.A., Lee P.W.K. Reovirus therapy of tumors with activated Ras pathway. Science. 282:1998;1332-1334.
116. Schirrmacher V., Haas C. Modification of cancer vaccines by virus infection and attachment of bispecific antibodies. An effective alternative to somatic gene therapy. Adv. Exp. Med. Biol. 451:1998;251-257.
117. Schirrmacher V., Ahlert T., Probstle T., et al. Immunization with virus-modified tumor cells. Semin. Oncol. 25:1998;677-696.
118. Haas C., Herold-Mende C., Gerhards R., Schirrmacher V. An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules. Cancer Gene Ther. 6:1999;254-262.
119. Schirrmacher V. Newcastle Disease virus in tumor therapy. Program booklet from "cytoreductive gene therapy": Harold W. Siebens Conference, September 25-27, 1999, Rochester, MN.
120. Reid T., Galanis E., Abbruzzese J., Sze D., et al. Hepatic artery infusion of Onyx-015, a selectively-replicating adenovirus, in combination with 5-FU/leucovorin for gastrointestinal carcinoma metastatic to the liver: a phase I/II trial. ASCO Proc. 19:2000;246a.
121. Simons J.W., Mikhak B., Van Der Poel H.G., DeMarzo A., et al. Molecular and clinical activity of CN706, a PSA-selective oncolytic AD5 vector in a phase I trial in locally recurrent prostate cancer following radiation therapy. Mol. Ther. 1:(5):2000;S144-S145.
122. Marshall E. Clinical trials: gene therapy death prompts review of adenovirus vector. Science. 286:1999;2244-2245.
123. Hallenbeck P.L., Chang Y.N., Hay C., Golightly D., et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10:(10):1999;1721-1733.
124. Kurihara T., Brough D.E., Kovesdi I., Kufe D.W. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. 106:(6):2000;763-771.